Cargando…
Structural Identification of Modified Amino Acids on the Interface between EPO and Its Receptor from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis
Protein modifications of recombinant pharmaceuticals have been observed both in vitro and in vivo. These modifications may result in lower efficacy, as well as bioavailability changes and antigenicity among the protein pharmaceuticals. Therefore, the contents of modification should be monitored for...
Autores principales: | Song, Kwang-Eun, Byeon, Jaehee, Moon, Dae-Bong, Kim, Hyong-Ha, Choi, Yoo-Joo, Suh, Jung-Keun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Molecular and Cellular Biology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255102/ https://www.ncbi.nlm.nih.gov/pubmed/25284312 http://dx.doi.org/10.14348/molcells.2014.0214 |
Ejemplares similares
-
Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis
por: Byeon, Jaehee, et al.
Publicado: (2015) -
Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis
por: Vočanec, Danijela, et al.
Publicado: (2018) -
Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011) -
How to pursue EPO in MS
por: Bartels, Claudia, et al.
Publicado: (2017) -
Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)